Comparison of danaparoid and unfractionated heparin in patients with obstetric antiphospholipid syndrome

Comparison of danaparoid and unfractionated heparin in patients with obstetric antiphospholipid syndrome - Comparison of danaparoid and unfractionated heparin in patients with obstetric antiphospholipid syndrome

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031012

Enrollment

Registered

2018-01-26

Start date

2005-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent pregnancy loss

Interventions

danaparoid sojium (Orgaran)+low dose aspirin unfractionated heparin+low dose aspirin low dose aspirin alone

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Antiphospholipid syndrome (APS) diagnosed according to criteria of the International Congress on APS

Exclusion criteria

Exclusion criteria: patients with congenital uterine anomaly, translocation

Design outcomes

Primary

Measure	Time frame
Live birth rate	—

Secondary

Measure	Time frame
Preterm birth, Pregnancy induced hypertension, Low birth weight, Bleeding, Thrombocytopenia, Osteopolosis	—

Countries

Japan

Contacts

Public ContactMayumi Sugiura-Ogasawara

Nagoya City University, Graduate School of Medical Sciences Obstetrics and Gynecology

og.mym@med.nagoya-cu.ac.jp052-851-5511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026